ClinicalTrials.gg
Not yet recruitingNCT07818512PINB-CPSPUpdated Sep 30, 2026

Parasternal Intercostal Nerve Block and Chronic Pain After Cardiac Surgery

An interventional study of Ultrasound-Guided Parasternal Intercostal Nerve Block and Bupivacaine 0.25% in Chronic Postoperative Pain, Chronic Post-Sternotomy Pain and CABG, sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Not applicable, Interventional, and Prevention

Updated Sep 30, 2026Start date movedEnrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Chronic post-sternotomy pain is a common but under-recognised complication of cardiac surgery, reported in roughly 11 to 56 percent of patients and capable of persisting for years after the operation. Effective control of pain in the early postoperative period is thought to reduce the central sensitisation that drives the transition from acute to chronic pain.

This single-centre, prospective, randomised, patient- and assessor-blinded controlled trial investigates whether an ultrasound-guided bilateral parasternal intercostal nerve block, performed preemptively after induction of general anaesthesia and before surgical incision, reduces the incidence of chronic pain three months after cardiac surgery performed through a median sternotomy.

A total of 132 adults scheduled for elective cardiac surgery will be randomised in a 1:1 ratio to receive either the block plus the institution's standard multimodal analgesia protocol, or the standard protocol alone. The primary endpoint is the incidence of chronic post-sternotomy pain at three months, assessed with the Turkish version of the Brief Pain Inventory - Short Form. Secondary endpoints cover acute pain scores, opioid consumption, postoperative nausea and vomiting, and complications.

Read the detailed description

Design and setting. The trial will be conducted in the Department of Anesthesiology and Reanimation, University of Health Sciences Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital. Eligible patients will be identified at the preoperative anaesthesia assessment and written informed consent will be obtained.

Randomisation and blinding. Participants will be allocated 1:1 using sequentially numbered, opaque, sealed envelopes prepared in advance. Patients and the investigator performing postoperative assessments will be unaware of group assignment; the anaesthesiologist performing the block cannot be blinded.

Intervention. In the block group, after induction of general anaesthesia and before surgical incision, a bilateral parasternal intercostal nerve block will be performed in the supine position with a high-frequency linear ultrasound probe (6-15 MHz) and a 22 G, 80 mm echogenic block needle.

Anaesthetic and analgesic management, identical in both groups.

Assessments. Pain is scored with the Numeric Rating Scale at rest and on movement at 0, 3, 6, 12, 18 and 24 hours after extubation. Opioid consumption, postoperative nausea and vomiting and any complications are recorded. At three months patients are contacted by telephone and assessed with the Brief Pain Inventory - Short Form, validated in Turkish by Ataman and colleagues.

Sample size. The calculation is based on the primary endpoint. 66 participants per group will be enrolled, for a total of 132.

02

Conditions studied

  • Chronic Postoperative Pain
  • Chronic Post-Sternotomy Pain
  • CABG
  • Sternotomy

Browse trials for

Keywords

  • parasternal intercostal nerve block
  • PINB
  • chronic post-sternotomy pain
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 132 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Bakirkoy Dr. Sadi Konuk Research and Training Hospital is the lead sponsor of 122 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years

    • Scheduled for elective cardiac surgery via median sternotomy
    • Able to understand and use the Numeric Rating Scale for pain
    • Willing to participate and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Surgery planned by a minimally invasive or thoracoscopic approach
  • Refusal to participate
  • Known allergy to the local anaesthetics or analgesics to be used
  • Chronic opioid use
  • Coagulopathy
  • Infection at the planned block site
  • Pregnancy or lactation
  • Inability to communicate or to score pain reliably
  • Psychiatric or neurological condition preventing reliable completion of the BPI-SF and NRS assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    PINB Group

    After induction of general anaesthesia and before surgical incision, participants receive an ultrasound-guided bilateral parasternal intercostal nerve block, in addition to the institutional standard perioperative analgesia protocol.

    Procedure: Ultrasound-Guided Parasternal Intercostal Nerve Block · Drug: Bupivacaine 0.25%

  • No intervention
    Control Group

    No regional block is performed. Participants receive only the institutional standard perioperative multimodal analgesia protocol, identical to that given to the block group.

Interventions

  • ProcedureUltrasound-Guided Parasternal Intercostal Nerve Block

    Performed in the supine position after induction of general anaesthesia and before surgical incision, using a 6-15 MHz linear ultrasound probe and a 22 G, 80 mm echogenic block needle.

  • 0.25 percent bupivacaine administered bilaterally as a single preemptive dose for the parasternal intercostal nerve block.

06

What researchers measure

Primary outcomes

  1. Incidence of chronic post-sternotomy pain at three months

    Time frame: 3 months after surgery

  2. Incidence of chronic post-sternotomy pain at three months

    Proportion of participants reporting pain in the sternotomy region three months after surgery, assessed by telephone with the Turkish Brief Pain Inventory - Short Form (BPI-SF). Chronic pain is defined as a reported pain score above 0 on the 0-10 numeric scale, at rest or on movement, persisting for more than three months after the operation.

    Time frame: 3 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kleiman AM, Sanders DT, Nemergut EC, Huffmyer JL. Chronic Poststernotomy Pain: Incidence, Risk Factors, Treatment, Prevention, and the Anesthesiologist's Role. Reg Anesth Pain Med. 2017 Nov/Dec;42(6):698-708. doi: 10.1097/AAP.0000000000000663. PubMed 28937533 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2027, 13 months later.

Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 13 months is above that.

Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartEst.
Sep 28, 2026was Aug 2026
Primary completionEst.
Nov 25, 2027
CompletionEst.
Aug 25, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 25, 2026→Sep 28, 2026
Sep 30, 2026
Enrollment
174→132
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Aug 25, 2026→Sep 28, 2026
    Enrollment 174→132
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07818512
Responsible party
İlayda Kalyoncu Karahan (Specialist Doctor (MD), Department of Anesthesiology and Reanimation, Bakirkoy Dr. Sadi Konuk Research and Training Hospital) — Principal investigator
First posted
Sep 14, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
Nov 25, 2027 (estimated)
Completion
Aug 25, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Ilayda Kalyoncu Karahan, MD
Contact
ilaydaakalyoncu@gmail.com
00905325105014

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion